<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005579</url>
  </required_header>
  <id_info>
    <org_study_id>VCC-9802</org_study_id>
    <secondary_id>CDR0000066360</secondary_id>
    <secondary_id>NCI-T98-0007</secondary_id>
    <nct_id>NCT00005579</nct_id>
  </id_info>
  <brief_title>Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Phase II Trial of Dolastin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with
      indolent lymphoma, Waldenstrom's macroglobulinemia, or chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Estimate the efficacy of dolastatin 10 in patients with indolent lymphoma, Waldenstrom's
           macroglobulinemia, or chronic lymphocytic leukemia.

        -  Evaluate the qualitative and quantitative toxicities of dolastatin 10 in this patient
           population.

        -  Investigate the mechanism of action of dolastatin 10 in regards to apoptosis and effects
           of microtubules.

      OUTLINE: This is an open-label, multicenter study. Patients are stratified by disease
      (chronic lymphocytic leukemia vs indolent lymphoma vs Waldenstrom's macroglobulinemia).

      All patients receive dolastatin 10 IV bolus every 3 weeks. Patients continue treatment until
      disease progression, unacceptable toxicity, or patient's withdrawal from the study.

      PROJECTED ACCRUAL: A maximum of 74 patients will be accrued for this study over 15 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolastatin 10</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologic or cytologic diagnosis of indolent lymphoma as defined by International
             Working Formulation categories A-C or diagnosis of Waldenstrom's macroglobulinemia, or
             chronic lymphocytic leukemia

          -  Lymphoma must be stage III, IV, or recurrent (no primary CNS lymphoma or lymphomatous
             meningitis)

          -  Waldenstrom's macroglobulinemia must have at least one of the following:

               -  IGM greater than 3,000 mg/dL

               -  Hemoglobin less than 10.0 g/dL

               -  Bone marrow involvement greater than 30% lymphocytes

               -  At least 2 cm lymphadenopathy

               -  Serum viscosity greater than 3.0

          -  Chronic lymphocytic leukemia must be intermediate or high risk stages I-IV and have
             progressed on fludarabine therapy unless patient cannot tolerate fludarabine

               -  Intermediate risk group must have at least one indication of active disease:

                    -  Presence of any one of the disease related B symptoms: 10% or more loss of
                       body weight over the preceding 6 month period, extreme fatigue, fever above
                       100 degrees F without evidence of infection, or night sweats

                    -  Massive (greater than 6 cm below left costal margin) or progressive
                       splenomegaly

                    -  Massive (greater than 10 cm in longest diameter) or progressive
                       lymphadenopathy

                    -  Progressive lymphocytosis with an increase of 50% over a 2 month period or
                       anticipated doubling time of less than 12 months

                    -  Evidence of progressive marrow failure as manifested by the development or
                       worsening of anemia and/or thrombocytopenia

                    -  Autoimmune anemia and/or thrombocytopenia poorly responsive to
                       corticosteroid therapy

          -  Intolerance, relapse, or failure following prior fludarabine allowed

          -  Measurable or evaluable disease

          -  No untreated immediate life threatening tumor complications

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  CALGB 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

          -  WBC at least 4,000/mm^3*

          -  Absolute granulocyte count at least 1,500/mm^3*

          -  Platelet count at least 100,000/mm^3*

          -  Hemoglobin at least 9 g/dL* NOTE: *Unless documented bone marrow involvement

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  SGOT no greater than 2.5 times upper limit of normal

        Renal:

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance at least 60 mL/min

        Other:

          -  No prior malignancy except adequately treated basal or squamous cell skin cancer,
             carcinoma in situ of the cervix, well differentiated stage IA prostate cancer, or any
             other cancer from which the patient has been disease free for five years

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior autologous bone marrow or stem cell transplantation

        Chemotherapy:

          -  See Disease Characteristics

          -  No more than 2 prior systemic regimens for treatment of lymphoma

          -  No chemotherapy for treatment of any other prior malignancy

          -  At least 4 weeks since chemotherapy and recovered

          -  Prior fludarabine therapy allowed

        Endocrine therapy:

          -  See Disease Characteristics

        Radiotherapy:

          -  Prior radiotherapy allowed (index lesion cannot be within prior radiotherapy field)

        Surgery:

          -  Recovered from prior surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M. Grunberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marlene and Stewart Greenebaum Cancer Center, University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital - Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401-3498</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolastatin 10</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

